Q2. Will management verify there is a high probability of recruiting 60 patients in a timely manner from specific centers (or centres) and countries prior to formerly committing to a phase 2 GvHD trial?"
The GVHD 'progress' has always been provisioned against finding someone that will pay for it. Forget the centres and patients - that comes after the provision is met.
Having started planning and building of expectation that candidates are to be enrolled by the end of the year, is pure folly, if there is no money to pay for it. Can we expect a positive announcement before another announcement shortly after saying the trial is stalled/dropped?
There is a team at the FDA, at the ready, waiting for CYP to give them the nod and then they will spring into action to ensure that CYP's requirements and expectations are met because the FDA has heard about CYP's 'at scale' capabilities.
Ask them what their expectations are as to 'doing a deal' with a 'partner' so that candidates get enrolled by the end of the year, because they have already started planning the project.
Ask them to elaborate on the OA trial finishing in 2024 when the trial completes 2 years after the final 440th candidate is enrolled? DO NOT ask them how many candidates are already enrolled.
In summary, you could ask: Who (apart from Hector) is buying this tripe?
CYP Price at posting:
33.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)